B022

B022 is a potent and selective NF-κB-inducing kinase (NIK) inhibitor (K_i of 4.2 nM; IC₅₀=15.1 nM). B022 protects liver from toxin-induced inflammation, oxidative stress, and injury^[1][2]. B022 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. IC50 & Target: Ki: 4.2 nM (NF-κB-inducing kinase (NIK))^[1] In Vitro: B022 (0-5 μM; 12 hours; Hepa1 cells) treatment suppresses NIK-induced p52 formation in a dose-dependent manner^[1].
B022 (0-5 μM; 12 hours; Hepa1 cells) treatment for 8 h completely blocks NIK-induced expression of TNF-a, IL-6, iNOS, CCL2, and CXCL5^[1].
B022 prevents NIK- or H2O2-induced β cell death and also ameliorates streptozotocin (STZ)-induced β cell death and hyperglycemia^[3]. In Vivo: B022 (30 mg/kg; intravenous injection; twice a day; for 10 days; STOP-NIK male mice) treatment inhibits NIK-triggered liver inflammation and injury in STOP-NIK mice infected with cre adenoviruses^[1].